SPONSOR
Laboratorio Elea Phoenix S.A.
Total Trials
2
Recruiting
2
Phases
Phase 3
Laboratorio Elea Phoenix S.A. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Non Small Cell Lung Cancer Metastatic, Chagas Disease.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Laboratorio Elea Phoenix S.A.
How many clinical trials has Laboratorio Elea Phoenix S.A. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Laboratorio Elea Phoenix S.A., of which 2 are actively recruiting participants. These trials cover conditions including Non Small Cell Lung Cancer Metastatic, Chagas Disease. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Laboratorio Elea Phoenix S.A. research focus on?
Laboratorio Elea Phoenix S.A. clinical trials span Non Small Cell Lung Cancer Metastatic, Chagas Disease. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Laboratorio Elea Phoenix S.A. clinical trial?
To participate in a Laboratorio Elea Phoenix S.A. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Laboratorio Elea Phoenix S.A. trials with current recruitment status updated daily.
Clinical Trials by Laboratorio Elea Phoenix S.A.
NCT05668650 Phase 3
Recruiting
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
Non Small Cell Lung Cancer Metastatic
NCT04897516 Phase 3
Recruiting
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Chagas Disease
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology